Addressing the Challenge of Common Chronic Diseases — A View from the FDA

Chronic diseases, including heart disease, cancer, diabetes, and liver disease, account for seven of the ten leading causes of death in the U.S. and contribute to declining life expectancy. The FDA emphasizes the need for innovative approaches to evidence generation, such as pragmatic trials and AI enhanced surveillance, to address these conditions. Strategies include improving biomarker development, fostering patient centered research, and enhancing prevention efforts in nutrition and tobacco control. The FDA is advancing initiatives to support diverse clinical trials, refine nutrition labeling, and reduce nicotine addiction. Collaboration across sectors is essential to mitigate disparities and improve health outcomes for marginalized populations.

Chronic diseases, including heart disease, cancer, diabetes, and liver disease, account for seven of the ten leading causes of death in the U.S. and contribute to declining life expectancy. The FDA emphasizes the need for innovative approaches to evidence generation, such as pragmatic trials and AI enhanced surveillance, to address these conditions. Strategies include improving biomarker development, fostering patient centered research, and enhancing prevention efforts in nutrition and tobacco control. The FDA is advancing initiatives to support diverse clinical trials, refine nutrition labeling, and reduce nicotine addiction. Collaboration across sectors is essential to mitigate disparities and improve health outcomes for marginalized populations.